330 Bibliografia [1] Carvalho AS, Lagana D, Catford J, Shaw D, Bak N. Bloodstream infections in neutropenic patients with haematological malignancies. Infect Dis Health. 2020 Feb;25(1):22-29. doi: 10.1016/j. idh.2019.08.006. Epub 2019 Oct 2. PMID: 31586572 [2] Connelly JA, Walkovich K. Diagnosis and therapeutic decision-making for the neutropenic patient. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):492-503. doi: 10.1182/ hematology.2021000284. PMID: 34889413; PMCID: PMC8791128 [3] Keng MK, Sekeres MA. Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep. 2013 Dec;8(4):370-8. doi: 10.1007/s11899-013-0171-4. PMID: 23990311 [4] Nucci M. How I Treat Febrile Neutropenia. Mediterr J Hematol Infect Dis. 2021 Mar 1;13(1):e2021025. doi: 10.4084/MJHID.2021.025. PMID: 33747406; PMCID: PMC7938921 [5] Kochanek M, Schalk E, von Bergwelt-Baildon M, Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2019 May;98(5):1051-1069. doi: 10.1007/s00277-019-03622-0. Epub 2019 Feb 22. PMID: 30796468; PMCID: PMC6469653 [6] Tavakoli A, Carannante A. Nursing Care of Oncology Patients with Sepsis. Semin Oncol Nurs. 2021 Apr;37(2):151130. doi: 10.1016/j. soncn.2021.151130. Epub 2021 Mar 13. PMID: 33722431 [7] Zimmer AJ, Freifeld AG. Optimal Management of Neutropenic Fever in Patients With Cancer. J Oncol Pract. 2019 Jan;15(1):19-24. doi: 10.1200/JOP.18.00269. PMID: 30629902 [8] Guarana M, Nucci M, Nouér SA. Shock and Early Death in Hematologic Patients with Febrile Neutropenia. Antimicrob Agents Chemother. 2019 Oct 22;63(11):e01250-19. doi: 10.1128/AAC.0125019. PMID: 31405857; PMCID: PMC6811434 [9] Escrihuela-Vidal F, Laporte J, Albasanz-Puig A, Gudiol C. Update on the management of febrile neutropenia in hematologic patients. Rev Esp Quimioter. 2019 Sep;32 Suppl 2(Suppl 2):5558. PMID: 31475812; PMCID: PMC6755372 [10] Ferrer R, Kumar A (2017) Surviving Sepsis campaign: international guidelines for management of sepsis and septic shock:2016. Intensive Care Med 43:304–377. https://doi. org/10.1007/s00134-017-4683-6 [11] Kochanek M, Schalk E, von Bergwelt-Baildon M, et al. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2019;98(5):1051–1069 [12] Kern WV, Roth JA, Bertz H, et al. Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: Results from a multicentric surveillance cohort study. Transpl Infect Dis. 2019;21(6):e13186 [13] Wingard J. Treatment of neutropenic fever syndrome in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). In: Bow E, Bond S, eds. UpToDate. Waltham, MA: UpToDate; 2020. Retrieved: 12/21/2020 from Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients) -UpToDate [14] Paul M, Borok S, Fraser A, Vidal L, Leibovici L. 2005. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55:436–444. doi: 10.1093/jac/ dki028 [15] Samonis G, Vardakas KZ, Maraki S, Tansarli GS, Dimopoulou D, Kofteridis DP, Andrianaki AM, Falagas ME. 2013. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 21:2521–2526. doi: 10.1007/s00520-013-1816-5
RkJQdWJsaXNoZXIy ODUzNzk5